Related Experiment Video
Updated: Sep 26, 2025

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
To Study the Clinical Profile of Thromboembolic Events in Covid 19 Patients
Anan1, Dilip Patil1, Pragnesh Shah1
1Acpm Medical College, Dhule.
Insights
Thromboembolism in severe COVID-19 patients significantly increases mortality risk. Early identification and management of thromboembolic events are crucial for improving survival outcomes in these critically ill individuals.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Cardiovascular Medicine
Background:
- Severe COVID-19 is characterized by systemic inflammation, coagulation activation, and multiorgan failure.
- Patients with severe COVID-19 often require intensive care unit (ICU) admission due to complications like acute respiratory distress syndrome (ARDS).
- Proinflammatory cytokines contribute to a 'cytokine storm,' exacerbating disease severity.
Purpose of the Study:
- To investigate the incidence and impact of thromboembolism in patients with severe COVID-19.
- To compare clinical and laboratory characteristics between severe COVID-19 patients with and without thromboembolism.
- To determine the association between thromboembolism and mortality in severe COVID-19.
Main Methods:
- A retrospective, cross-sectional study of 154 severe COVID-19 patients.
- Patients were categorized into those with (38) and without (116) thromboembolism.
- Clinical data, laboratory markers, and survival outcomes were analyzed.
Main Results:
- Thromboembolism occurred in 24.67% of severe COVID-19 patients.
- Patients with thromboembolism were older, more likely to require mechanical ventilation and ICU admission, and had higher mortality.
- Elevated inflammatory markers, D-dimer, and N-terminal pro-brain natriuretic peptide were associated with thromboembolism.
Conclusions:
- Thromboembolism is associated with significantly higher mortality in severe COVID-19.
- The incidence of thromboembolism increases the risk of death in severe COVID-19 patients.
- Further research into preventative and therapeutic strategies for thromboembolism in severe COVID-19 is warranted.
Abstract:
The sars -cov 2 causing covid 19 disease. B/l pneumonia, systemic inflammation, coagulation activation, ards , multiorgan failure are key features of covid 19. Patients need icu admission. Proinflammatory cytokines, tnf, il 6, 8, 1 beta, causes cytokine storm in covid 19 disease.
Material:
In this single-center, retrospective, cross sectional study, the clinical and laboratory characteristics of 154 patients with severe covid-19 were collected. 38 Patients with severe covid -19 had incidence of thromboembolism with its symptoms, and 116 patients (ie, the controls) did not have incidence of thromboembolism. A severe case was defined as including at least one of the following criteria: (1) respiratory rate >30/ min. (2) Oxygen saturation ≤90%. (3) Pao2 /fio2 ≤300mm hg. (4) Patients, either with shock or respiratory failure, requiring mechanical ventilation, or combined with other organ failure, requiring admission to intensive care unit (icu). Also pe cases were those patients with high clinical suspicion [tachycardia >100 bpm, systolic arterial tension <100 mmhg or signs of right ventricular pressure overload]. Pe severity was assessed using the simplified pulmonary embolism severity index (s -pesi).
Observation:
Of 154 patients with severe covid-19, 38 (24.67%) Had incidence of thromboembolism. Compared with patients with severe covid-19 without incidence of thromboembolism, patients with incidence of thromboembolism were older, susceptible to receiving mechanical ventilation and admission to icu, and had higher mortality. In addition, patients with severe covid-19 with thromboembolism had higher levels of leukocyte count, neutrophil count, high-sensitivity c reaction protein, procalcitonin, ferritin, interleukin (il) 2 receptor, il-6, il-8, tumor necrosis factor α, D-dimer, fibrinogen, lactic dehydrogenase and n-terminal probrain natriuretic peptide. Among patients with severe covid-19 with incidence of thromboembolism, more non-survivors were men (30 (75%) vs women (25%)). Non-survivors had severe inflammatory response, and cardiac, hepatic, renal and coagulation impairment. Finally, the kaplan-meier survival curve showed a trend towards poorer survival in patients with severe covid-19 with incidence of thromboembolism than patients without incidence of thromboembolism. The hr was 2.24 [95% Ci 1.17-4.29], P = 0.015). After adjustment for age, sex, hypertension, cardiovascular disease and cerebrovascular disease by cox regression. The median survival durations from hospital admission in patients with severe covid-19 with and without incidence of thromboembolism were 8 days and 15 days, respectively.
Conclusion:
The mortality rate in patients with severe covid-19 with incidence of thromboembolism is high. Incidence of thromboembolism may lead to an increase in the risk of death.
Related Concept Videos
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism I: Introduction
Venous Thrombosis I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

